Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting

2025-521003-52-00 HER2 Expressing Advanced Breast Cancer 2025-12-19
A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia Recruiting

2024-519745-30-01 Immune Thrombocytopenia (ITP) 2025-12-19
To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan… Recruiting

2025-521128-31-00 Locally Advanced or Metastatic Estrogen Receptor-Positi 2025-12-18
Guanabenz in VWM: extension study Recruiting

2024-518834-95-02 Vanishing white matter 2025-12-08
A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting

2024-517261-16-00 Advanced solid tumors 2025-12-05
A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors Recruiting

2025-522274-37-00 Neoplasms 2025-12-03
CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the … Recruiting

2023-508861-34-00 Pneumocystis pneumonia 2025-12-02
Prospective cohort involving repeated medical PET-CT imaging with a new radiotracer (FAPI) Recruiting

2024-512467-31-00 Non-metastatic Pancreatic ductal adenocarcinoma 2025-12-02
A Study of the Long-Term Safety and Efficacy of VX-670 in Patients With Myotonic Dystrophy Type I Recruiting

2024-517983-47-00 Myotonic Dystrophy 2025-11-25
The headache-inducing effects of cilostazol in men and women with migraine without aura Recruiting

2025-521520-29-00 Migraine 2025-11-21
TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t… Recruiting

2023-510568-11-00 High grade brain tumors 2025-11-18
Longitudinal study with positron emission tomography using [18F]PI-2620 in primary tauopathies. Proof-of-concept study Recruiting

2025-522826-11-00 Corticobasal syndrome (CBS) 2025-11-06
TransBronchial Needle injection of Tremelimumab in early-stage NSCLC patients (TALENT) Recruiting

2024-511878-67-00 Non small cell lung cancer 2025-11-03
A Phase 1b/2, Study of I-DXd in Combination with Atezolizumab with or without Carboplatin in First-line ES‑SCLC Recruiting

2023-509629-36-00 Extensive-stage Small Cell Lung Cancer (ES-SCLC) 2025-10-29
Oxytocin and attachment development: Looking beyond the expected? Recruiting

2024-518004-49-00 Healthy children 2025-10-28
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim… Recruiting

2024-517140-65-00 Multiple Myeloma (MM). 2025-10-23
Neoadjuvant Cemiplimab Plus Imiquimod in Cutaneous Basal Cell Carcinoma. Recruiting

2025-520698-38-00 Cutaneous Basal Cell Carcinoma 2025-10-22
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Relapsed or Refractory B-Cell Malignancies 2025-10-15
Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea… Recruiting

2024-511459-16-00 Histologically confirmed pancreatic adenocarcinoma with 2025-10-14
Evaluation of Multiparametric dynamic whole-body 68Ga-PSMA PET imaging for Hepatocellular Carcinoma recurrence. HIMIKO study. Recruiting

2024-515178-28-00 Hepatocellular carcinoma 2025-09-23
Towards improved therapy selection and targeted treatment for nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin rece… Recruiting

2025-520689-23-00 nasopharyngeal carcinoma 2025-09-22
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting

2024-513613-12-00 Part A: Healthy volunteers (Part A is not applicable to 2025-09-18
Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting

2025-520672-26-00 Gastrointestinal Neoplasms 2025-09-16
A pilot, multicentre, controlled, open-label study evaluating 24 months of lithium carbonate treatment in patients with TBR1-related neuroco… Recruiting

2024-513955-34-00 Proven pathogenic or probably pathogenic TBR1 variant 2025-09-09